Cas:20175-84-2 isodiospyrin manufacturer & supplier

Chemical Name:isodiospyrin

CAS.NO:20175-84-2

Synonyms:Isodiospirin;(1,2′-Binaphthalene)-5,5′,8,8′-tetrone, 1′,4-dihydroxy-2,3′-dimethyl-, (-)-;[1,2′-Binaphthalene]-5,5′,8,8′-tetrone, 1′,4-dihydroxy-2,3′-dimethyl-, (-)-;1′,4-Dihydroxy-2,3′-dimethyl-1,2′-binaphthalene-5,5′,8,8′-tetrone;isodiospyrin;[1,2′-Binaphthalene]-5,5′,8,8′-tetrone, 1′,4-dihydroxy-2,3′-dimethyl-

Molecular Formula:C₂₂H₁₄O₆

Molecular Weight:374.343

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:712.0±60.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.707

PSA:108.74000

Exact Mass:374.079041

LogP:3.83

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Isodiospirin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[1,2′-Binaphthalene]-5,5′,8,8′-tetrone, 1′,4-dihydroxy-2,3′-dimethyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[1,2′-Binaphthalene]-5,5′,8,8′-tetrone, 1′,4-dihydroxy-2,3′-dimethyl- Use and application,Isodiospirin technical grade,usp/ep/jp grade.

Related News: Besides McNamara’s hire, GSK said it’s expected to name a chair for the OTC firm later this year, who will then establish the board. (1R,3aS,4S,5R,6aR,7S,9aS,10R,10aS)-7-Isopropyl-5-methoxymethoxy-1,4-dimethyl-tetradecahydro-dicyclopenta[a,d]cycloocten-10-ol manufacturers Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. 3-chloro-6-(3,4,5-trimethoxy-phenyl)-pyridazine suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 2-Benzofurancarboxylic acid, 3-methyl-7-oxiranyl-, ethyl ester vendor & factory.